Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
9 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Celcuity Inc.’s names, not what it holds today.
Patents granted
9
9 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against none in 2024 and 1 in 2023
Applications published
14
1 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'13'15'16'17'18'19'21'22'23'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Analysis of biological materials3
Pharmaceuticals2
Biotechnology2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Celcuity Inc. its own name
named as the applicant on its applications, in US
12 publishedCelcuity Inc. its own name
US, as the owner printed on each patent
2 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Jul 8, 2025 | 12,350,276 | Methods for the treatment of cancer using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea | Pharmaceuticals | Celcuity Inc. |
| Jun 3, 2025 | 12,320,799 | Methods of measuring signaling pathway activity for selection of therapeutic agents | Analysis of biological materials | Celcuity Inc. |
| Feb 4, 2025 | 12,215,356 | Methods of preparing a primary cell sample | Biotechnology | Celcuity Inc. |
| Feb 28, 2023 | 11,591,573 | Methods of preparing a primary cell sample | Biotechnology | Celcuity Inc. |
| May 17, 2022 | 11,333,659 | Methods of measuring signaling pathway activity for selection of therapeutic agents | Analysis of biological materials | Celcuity Inc. |
| Jul 27, 2021 | 11,073,509 | Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent | Pharmaceuticals | Celcuity Inc. |
| Apr 13, 2021 | 10,976,307 | Whole cell assays and methods | Analysis of biological materials | Celcuity Inc. |
| Aug 7, 2018 | 10,041,934 | Whole cell assays and methods | Analysis of biological materials | Celcuity Inc. |
| Aug 2, 2016 | 9,404,915 | Whole cell assays and methods | Analysis of biological materials | Celcuity Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Nov 13, 2025 | 2025/0345342 | METHODS FOR THE TREATMENT OF CANCER USING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA | Pharmaceuticals | Celcuity Inc. |
| Jul 27, 2023 | 2023/0235293 | METHODS OF PREPARING A PRIMARY CELL SAMPLE | Biotechnology | Celcuity Inc. · patent 12,215,356 granted from it |
| Apr 27, 2023 | 2023/0125427 | METHODS OF MEASURING SIGNALING PATHWAY ACTIVITY FOR SELECTION OF THERAPEUTIC AGENTS | Pharmaceuticals | Celcuity Inc. · patent 12,320,799 granted from it |
| Jan 26, 2023 | 2023/0022525 | METHODS FOR THE TREATMENT OF CANCER USING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA | Pharmaceuticals | Celcuity Inc. · patent 12,350,276 granted from it |
| Dec 29, 2022 | 2022/0412957 | METHODS OF TREATING CANCER PATIENTS WITH RAS NODE OR RTK TARGETED THERAPEUTIC AGENTS | Analysis of biological materials | Celcuity Inc. |
| Jul 15, 2021 | 2021/0215673 | WHOLE CELL ASSAYS AND METHODS | Analysis of biological materials | Celcuity Inc. |
| Jan 24, 2019 | 2019/0025287 | METHODS OF MEASURING SIGNALING PATHWAY ACTIVITY FOR SELECTION OF THERAPEUTIC AGENTS | Pharmaceuticals | Celcuity Inc. · patent 11,333,659 granted from it |
| Nov 8, 2018 | 2018/0321222 | WHOLE CELL ASSAYS AND METHODS | Analysis of biological materials | Celcuity Inc. · patent 10,976,307 granted from it |
| Aug 16, 2018 | 2018/0230434 | METHODS OF PREPARING A PRIMARY CELL SAMPLE | Biotechnology | Celcuity Inc. · patent 11,591,573 granted from it |
| Nov 30, 2017 | 2017/0343554 | METHODS OF MEASURING ERBB SIGNALING PATHWAY ACTIVITY TO DIAGNOSE AND TREAT CANCER PATIENTS | Pharmaceuticals | Celcuity Inc. |
What it applied for, 2024 to 2025: Pharmaceuticals 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.